Lipohypertrophy in China: Prevalence, Risk Factors, Insulin Consumption, and Clinical Impact.

abstract：:Subcutaneous (s.c.) injections of identical insulin doses may lead to considerable intra- and inter-individual differences in the current metabolic control of patients with diabetes mellitus. This well-known variability of the metabolic effect of insulin hampers practical insulin therapy considerably. The aim of this ...

journal_title：Diabetes technology & therapeutics

authors： Heinemann L

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:The OpT2mise randomized trial was designed to compare the effects of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) on glucose profiles in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS:Patients with glycated hemoglobin (HbA1c) levels of ≥8% (64 mmol/mol) and...

journal_title：Diabetes technology & therapeutics

authors： Conget I,Castaneda J,Petrovski G,Guerci B,Racault AS,Reznik Y,Cohen O,Runzis S,de Portu S,Aronson R,OpT2mise Study Group.

更新日期：2016-01-01 00:00:00

abstract：: Background: The Medtronic MiniMed™ 670G system adjusts basal insulin delivery in response to continuous glucose monitoring levels and is already in use in clinical practice. We tested the home-based feasibility of the new MiniMed advanced hybrid closed-loop (AHCL) system, ...

journal_title：Diabetes technology & therapeutics

authors： Nimri R,Grosman B,Roy A,Nir J,Fisch Shvalb N,Kurtz N,Loewenthal N,Gillon-Keren M,Muller I,Atlas E,Phillip M

更新日期：2020-12-08 00:00:00

abstract：:Treatments for type 1 diabetes have advanced significantly over recent years. There are now multiple hybrid closed-loop systems commercially available and additional systems are in development. Challenges remain, however. This review outlines the recent advances in closed-loop systems and outlines the remaining challe...

journal_title：Diabetes technology & therapeutics

authors： Jackson M,Castle JR

更新日期：2020-07-01 00:00:00

abstract：BACKGROUND:The optimal treatment of diabetes in pregnancy requires accurate measurement of blood glucose levels, in order to minimize adverse outcomes for both mother and neonate. Self-monitoring of blood glucose is routinely used to measure glycemic control and to assess whether treatment targets are being met; howeve...

journal_title：Diabetes technology & therapeutics

authors： McGrath RT,Donnelly VC,Glastras SJ,Preda VA,Sheriff N,Ward P,Hocking SL,Fulcher GR

更新日期：2016-02-01 00:00:00

abstract：OBJECTIVE:Hemoglobin A1c (A1C) has recently been recommended for diagnosing diabetes mellitus and diabetes risk (prediabetes). Its performance compared with fasting plasma glucose (FPG) and 2-h post-glucose load (2HPG) is not well delineated. We compared the performance of A1C with that of FPG and 2HPG in preoperative ...

journal_title：Diabetes technology & therapeutics

authors： Gianchandani RY,Saberi S,Zrull CA,Patil PV,Jha L,Kling-Colson SC,Gandia KG,DuBois EC,Plunkett CD,Bodnar TW,Pop-Busui R

更新日期：2011-12-01 00:00:00

abstract：OBJECTIVE:This study was designed to assess whether waist circumference can predict metabolic syndrome abnormalities in primary schoolchildren. RESEARCH DESIGN AND METHODS:Of 5,103 children (2,526 males) 4-13 years old who underwent anthropometric measurements, 530 had more extensive testing. Body mass index (BMI), wa...

journal_title：Diabetes technology & therapeutics

authors： Hirschler V,Maccallini G,Calcagno M,Aranda C,Jadzinsky M

更新日期：2007-04-01 00:00:00

abstract：:Patients with diabetes play with a double-edged sword when it comes to deciding glucose and A1c target levels. On the one side, tight control has been shown to be crucial in avoiding long-term complications; on the other, tighter control leads to an increased risk of iatrogenic hypoglycemia, which is compounded when h...

journal_title：Diabetes technology & therapeutics

authors： Palerm CC,Willis JP,Desemone J,Bequette BW

更新日期：2005-02-01 00:00:00

abstract：:Laser retinal photocoagulation represents the primary therapy for the potentially blinding manifestations of diabetic retinopathy. Advances in laser therapy for diabetic eye disease have arisen from the convergence of laser technology and clinical ophthalmology. In this review, the basis of laser therapy in diabetic r...

journal_title：Diabetes technology & therapeutics

authors： Petrovic V,Bhisitkul RB

更新日期：1999-07-01 00:00:00

abstract：:Insulin infusion pump therapy has dramatically improved over the past 20 years and can now address some of the specific challenges related to toddlers with diabetes. We discuss both the non-randomized and randomized controlled trials comparing continuous subcutaneous insulin infusion (CSII) and multiple daily injectio...

journal_title：Diabetes technology & therapeutics

authors： Fuld K,Conrad B,Buckingham B,Wilson DM

更新日期：2010-06-01 00:00:00

abstract：PURPOSE:This study investigated reasons for the rejection and discontinuation of insulin pump therapy and explored general attitudes towards this mode of therapy among young patients with type 1 diabetes. METHODS:A questionnaire was developed using a focus group of young people with diabetes. It was then used to surve...

journal_title：Diabetes technology & therapeutics

authors： Seereiner S,Neeser K,Weber C,Schreiber K,Habacher W,Rakovac I,Beck P,Schmidt L,Pieber TR

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:The purpose of this study was to evaluate the performance of an insulin infusion protocol targeting a blood glucose (BG) level of 140-180 mg/dL and to characterize protocol adherence. MATERIALS AND METHODS:This was a retrospective observational cohort study including patients for whom the protocol was order...

journal_title：Diabetes technology & therapeutics

authors： Passarelli AJ,Gibbs H,Rowden AM,Efird L,Zink E,Mathioudakis N

更新日期：2016-02-01 00:00:00

abstract：: Background: The objective of this study was to assess the safety and performance of the Omnipod® personalized model predictive control (MPC) algorithm in adults, adolescents, and children aged ≥6 years with type 1 diabetes (T1D) under free-living conditions using an invest...

journal_title：Diabetes technology & therapeutics

authors： Sherr JL,Buckingham BA,Forlenza GP,Galderisi A,Ekhlaspour L,Wadwa RP,Carria L,Hsu L,Berget C,Peyser TA,Lee JB,O'Connor J,Dumais B,Huyett LM,Layne JE,Ly TT

更新日期：2020-03-01 00:00:00

abstract：:On May 26, 1976, the Food and Drug Administration (FDA) began implementing the Medical Device Amendments to the Federal Food Drug and Cosmetic Act. These amendments give FDA specific authority to regulate "medical devices." Additional authority was provided in the Safe Medical Devices Act of 1990. The pathways to get ...

journal_title：Diabetes technology & therapeutics

authors： Gutman S,Bernhardt P,Pinkos A,Moxey-Mims M,Knott T,Cooper J

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:A1chieve(®) (Novo Nordisk A/S, Bagsværd, Denmark) was a prospective, multicenter, noninterventional study in 66,726 people with type 2 diabetes mellitus (T2DM) in 28 countries beginning biphasic insulin aspart 30 (aspart premix), insulin detemir, or insulin aspart in routine clinical care. SUBJECTS AND METH...

journal_title：Diabetes technology & therapeutics

authors： Shah S,Yang W,Hasan MI,Malek R,Molskov Bech O,Home P

更新日期：2013-11-01 00:00:00

abstract：:Chronic hyperglycemia, as assessed by hemoglobin A1c (HbA1c) levels, has been associated with the development of microvascular and macrovascular complications of diabetes. Several studies have shown that acute hyperglycemia can add to the effect of chronic hyperglycemia in inducing tissue damage. Acute hyperglycemia c...

journal_title：Diabetes technology & therapeutics

authors： Marcovecchio ML,Lucantoni M,Chiarelli F

更新日期：2011-03-01 00:00:00

abstract：BACKGROUND:Faster aspart is insulin aspart (IAsp) in a new formulation, which in continuous subcutaneous insulin infusion (CSII) in subjects with type 1 diabetes has shown a faster onset and offset of glucose-lowering effect than IAsp. METHODS:This double-blind, randomized, crossover active-controlled trial compared 2...

journal_title：Diabetes technology & therapeutics

authors： Bode BW,Johnson JA,Hyveled L,Tamer SC,Demissie M

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND:Glucose monitoring based on sampling skin interstitial fluid (ISF) is being developed as an alternative to fingerstick blood glucose monitoring. Time delays between rapidly changing levels of glucose in blood and interstitial fluid have been reported in the literature to be between 5 and 20 minutes. This stu...

journal_title：Diabetes technology & therapeutics

authors： Smith A,Yang D,Delcher H,Eppstein J,Williams D,Wilkes S

更新日期：1999-04-01 00:00:00

abstract：BACKGROUND:Internet technology has been proven to be a successful tool for the management of patients with multiple medical conditions. The purpose of this study was to demonstrate the feasibility of monitoring glucose control in indigent women with gestational diabetes mellitus (GDM) over the Internet. METHODS:Women ...

journal_title：Diabetes technology & therapeutics

authors： Homko CJ,Santamore WP,Whiteman V,Bower M,Berger P,Geifman-Holtzman O,Bove AA

更新日期：2007-06-01 00:00:00

abstract：BACKGROUND:Insulin initiation and optimization is a challenge for patients with type 2 diabetes. Our objective was to determine whether safety and efficacy of AIR inhaled insulin (Eli Lilly and Co., Indianapolis, IN) (AIR is a registered trademark of Alkermes, Inc., Cambridge, MA) using a simplified regimen was noninfe...

journal_title：Diabetes technology & therapeutics

authors： Mathieu C,Cuddihy R,Arakaki RF,Belin RM,Planquois JM,Lyons JN,Heilmann CR

更新日期：2009-09-01 00:00:00

abstract：BACKGROUND:This study was designed to assess the accuracy, reliability, and contribution to clinical decision-making of two commercially available continuous glucose monitoring (CGM) devices using a novel analytical approach. STUDY DESIGN:Eleven individuals with type 1 diabetes and five with type 2 diabetes wore a Gua...

journal_title：Diabetes technology & therapeutics

authors： Mazze RS,Strock E,Borgman S,Wesley D,Stout P,Racchini J

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Implanted insulin pumps using the peritoneal route provide long-term improvement of glucose control compared with subcutaneous insulin therapy in type 1 diabetes (T1D) patients. The stability of insulin preparation is critical for a safe use in implanted pumps. Insuman implantable(®) (400 IU/mL) (Sanofi-Aven...

journal_title：Diabetes technology & therapeutics

authors： Schaepelynck P,Riveline JP,Renard E,Hanaire H,Guerci B,Baillot-Rudoni S,Sola-Gazagnes A,Catargi B,Fontaine P,Millot L,Martin JF,Tachouaft H,Jeandidier N,EVADIAC Group.

更新日期：2014-09-01 00:00:00

abstract：OBJECTIVE:Over the past 35 years considerable research has been performed toward the investigation of noninvasive and minimally invasive glucose monitoring techniques. Optical polarimetry is one noninvasive technique that has shown promise as a means to ascertain blood glucose levels through measuring the glucose conce...

journal_title：Diabetes technology & therapeutics

authors： Pirnstill CW,Malik BH,Gresham VC,Coté GL

更新日期：2012-09-01 00:00:00

abstract：BACKGROUND:The hyperinsulinemic euglycemic clamp is the gold standard for assessment of insulin resistance and requires frequent, accurate measurements of blood glucose concentrations, typically utilizing the YSI 2300 STAT Plus™ glucose analyzer (YSI, Inc., Yellow Springs, OH). Despite its accuracy, the YSI has several...

journal_title：Diabetes technology & therapeutics

authors： Lindquist KA,Chow K,West A,Pyle L,Isbell TS,Cree-Green M,Nadeau KJ

更新日期：2014-05-01 00:00:00

abstract：BACKGROUND:The efficacy of short-term professional continuous glucose monitoring (CGM) for glycemic control in patients with diabetes remains unclear. METHODS:We performed a 3-month study to evaluate the benefits of CGM in 64 patients. RESULTS:The overall glycemic control of patients who underwent CGM improved signif...

journal_title：Diabetes technology & therapeutics

authors： Shibusawa R,Yamada E,Okada S,Nakajima Y,Bastie CC,Yamada M

更新日期：2018-09-01 00:00:00

abstract：AIMS:This study evaluated treatment satisfaction, comfort, and function using the wireless OmniPod™ Insulin Management System (Insulet Corp., Bedford, MA) compared with conventional (infusion set) insulin pumps in young adults with type 1 diabetes. RESEARCH DESIGN AND METHODS:Twenty-nine patients (age, 24.0 ± 5.1 year...

journal_title：Diabetes technology & therapeutics

authors： Lebenthal Y,Lazar L,Benzaquen H,Shalitin S,Phillip M

更新日期：2012-05-01 00:00:00

abstract：:Measuring the hemoglobin A(1c) (HbA(1c)) is the standard-of-care method to assess long-term glycemic control of patients with diabetes, describing the average glycemic level. However, the HbA(1c) does not reflect acute fluctuations in glucose levels. Variability of glycemia probably has an impact on the development of...

journal_title：Diabetes technology & therapeutics

authors： Thomas A,Schönauer M,Achermann F,Schnell O,Hanefeld M,Ziegelasch HJ,Mastrototaro J,Heinemann L

更新日期：2009-06-01 00:00:00

abstract：BACKGROUND:Currently, it is still unknown whether differences in glycemic control have any effect on glucose and insulin kinetics after vildagliptin administration. The aim of this study was to evaluate the effect of vildagliptin on glucose and insulin concentrations during a 24-h period in type 2 diabetes patients wit...

journal_title：Diabetes technology & therapeutics

authors： González-Ortiz M,Sánchez-Peña MJ,González-Ortiz LJ,Robles-Cervantes JA,García-Ortega YE,Gómez-Gaitán EA,Pérez-Rubio KG,Martínez-Abundis E

更新日期：2013-07-01 00:00:00

abstract：:Basal insulin analogs are recognized as an effective method of achieving and maintaining glycemic control for patients with type 2 diabetes. However, the progressive nature of the disease means that some individuals may require additional ways to maintain their glycemic goals. Intensification in these circumstances ha...

journal_title：Diabetes technology & therapeutics

authors： Perfetti R

更新日期：2011-09-01 00:00:00

abstract：:Thanks to significant improvements in the precision, accuracy, and usability of continuous glucose monitoring (CGM), its relevance in both ambulatory diabetes care and clinical research is increasing. In this study, we address the latter perspective and derive provisional reporting recommendations. CGM systems have be...

journal_title：Diabetes technology & therapeutics

authors： Schnell O,Barnard K,Bergenstal R,Bosi E,Garg S,Guerci B,Haak T,Hirsch IB,Ji L,Joshi SR,Kamp M,Laffel L,Mathieu C,Polonsky WH,Snoek F,Home P

更新日期：2017-07-01 00:00:00